Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID)[2] marketed in the US as an ophthalmic solution (brand names Prolensa and Bromday,[3] prior formulation brand name Xibrom, which has since been discontinued) by ISTA Pharmaceuticals for short-term, local use.

[5][6] The drug has been shown to reduce macular edema and thickness of the retina (an indicator for inflammation) and improve visual acuity after surgery.

[4][8] Blood plasma levels remain very low during bromfenac therapy, so interactions with drugs taken by mouth are unlikely.

As an NSAID, bromfenac works by inhibiting prostaglandin synthesis by blocking the cyclooxygenase (COX) enzymes.

[14] Bromfenac was formerly marketed in the United States by Wyeth-Ayerst in an oral formulation called Duract for short-term relief of pain (less than 10 days at a time).

It was brought to market in July 1997, and was withdrawn 22 June 1998, following numerous reports of hepatotoxicity in patients who had taken the medication for longer than the recommended 10-day period.